HPPD and the Risks of Psychedelic Misuse with Ed Prideaux
Similar Posts
BIG NEWS on MindMed’s Clinical Trials [ Important MMED/MMEDF UPDATES You Need to Know ]
Hello Psychedelic Investors! Today, we will focus on MindMed’s 2021 Investors Deck and Project Lucy & Project Layla’s clinical trials updates.
MindMed, ticker symbol MMED on the Canadian NEO Stock exchange, and MMEDF on the American OTC Market has updated their 2021 Investors Deck (TWICE) in this year. As a fellow MindMed geek, I did my due diligence to compare the information on both decks and there’s a few clinical trial changes and a few other updates I found important to discuss.
In this episode, we will discuss:
Timecodes
0:00 – Intro
3:02 – MindMed’s Project Lucy Updates
6:27 – MMED’s18-MC And Microdosing Updates
9:00 – LSD to treat Suicide Headaches
11:04 – Phase 1 Updates
14:06 – Stats Updates
15:32 – MindMed Stock Speculation Zone
Important to mention that after we shot this video, MindMed did answer our inquiry about the removed readout with “Hello – Sorry for the delay. We plan on filing the IND for Project Lucy in Q3 of 2021.”
I’m not sure if that means that there will be a readout in Q3 as well…
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video by Pressmaster from Pexels
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMEDF #MindmedStock
More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)
Today we’ll discuss More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)
Today’s episode is a short follow up video to our last episode, where we looked at the catalysts for MindMed and MindMed stock in 2021.
We have already covered the NASDAQ uplisting, Clinical trial updates that MindMed will give this year and Conference calls and possible financing deals. But of course, we missed a few of important possible catalysts, as you guys so rightly pointed out.
So in this episode we are briefly going to run through them.
So what else can MindMed and MMED/MMEDF investors expect this year?
1. The imminent launch of the first Psychedelic Medicines ETF, The North American Psychedelics Index (PSYK)
-When will it launch?
-In what manner will it affect MindMed
-And how much it will influence MindMed’s stock price
2. Atai Life Sciences expected IPO how that’ll affect MindMed
– How will the IPO of another big rival will affect MMED/MMEDF?
3. Potential catalyst of Partnerships, Mergers and Acquisitions
-Coming directly from an Interview with JR Rahn and Kevin O’Leary
Unlike the 1st two catalysts we discuss here, as well as a potential Nasdaq uplisting, future partnerships mergers and acquisitions would affect MindMed’s long term value, and their ability to develop, produce and distribute game changing medicines.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
Amanita Muscaria and Desert Herbalism with Ash Ritter
We dive into the world of the infamous Amanita Muscaria mushroom and learn about the wild desert apothecary of fungi and herbs.
UFC Explores Psychedelic Therapy for Brain-Injured Fighters
The UFC (Ultimate Fighting Championship) is working with industry leaders to better understand brain trauma-related problems the combat sport causes athletes. As part of that effort, the organization is taking a long, hard look at psychedelic therapies as possible treatments.
Real Estate and Psychedelic-Assisted Therapy with Ty Zakovich, Daniel Carcillo, and Cody Shandraw
In this episode David Flores, CEO of Spotlight Media Corp, sits down with the founding members of the newly formed Healing REIT that will focus on investing in real estate designed for innovative medicine such as psychedelic-assisted therapy.